Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System.
Int J Environ Res Public Health
; 16(2)2019 01 21.
Article
em En
| MEDLINE
| ID: mdl-30669602
ABSTRACT
This study reviews and evaluates the national drug formulary system used to improve patient access to new drugs by making reimbursement decisions for new drugs as part of the South Korean national health insurance system. The national health insurance utilizes three methods for improving patient access to costly drugs risk-sharing agreements, designation of essential drugs, and a waiver of cost-effectiveness analysis. Patients want reimbursement for new drugs to be processed quickly to improve their access to these drugs, whereas payers are careful about listing them given the associated financial burden and the uncertainty in cost-effectiveness. However, pharmaceutical companies are advocating for drug prices above certain thresholds to maintain global pricing strategies, cover the costs of drug development, and fund future investments into research and development. The South Korean government is expected to develop policies that will improve patient access to drugs with unmet needs for broadening health insurance coverage. Simultaneously, the designing of post-listing management methods is warranted for effectively managing the financial resources of the national health insurance system.
Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
Bases de dados:
MEDLINE
Assunto principal:
Custos de Medicamentos
/
Formulários Farmacêuticos como Assunto
/
Acessibilidade aos Serviços de Saúde
/
Programas Nacionais de Saúde
Aspecto:
Determinantes_sociais_saude
Limite:
Humans
País/Região como assunto:
Asia
Idioma:
En
Revista:
Int J Environ Res Public Health
Ano de publicação:
2019
Tipo de documento:
Article